



Figure S3: (a-c) Baseline photograph of a patient of GROUP III (tazarotene 0.05%) with acne vulgaris showing a decrease in active acne lesions. (d-f) After 8 weeks.



Figure S4: (a-c) Baseline photograph of a patient of GROUP IV (tazarotene 0.1%) with acne vulgaris showing a decrease in active acne lesions. (d-f) After 8 weeks.